Galectin Therapeutics Stock Price, News & Analysis (NASDAQ:GALT)

$3.61
-0.12 (-3.22 %)
(As of 09/24/2019 04:34 AM ET)
Today's Range
$3.54
Now: $3.61
$3.89
50-Day Range
$3.02
MA: $3.44
$3.84
52-Week Range
$2.94
Now: $3.61
$6.85
Volume239,438 shs
Average Volume348,954 shs
Market Capitalization$204.44 million
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share

Profitability

Net Income$-13,900,000.00

Miscellaneous

Employees6
Market Cap$204.44 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.


Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Friday, August, 9th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View Galectin Therapeutics' Earnings History.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Galectin Therapeutics.

What price target have analysts set for GALT?

1 brokers have issued 1-year price targets for Galectin Therapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Galectin Therapeutics' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 204.7% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.

What is the consensus analysts' recommendation for Galectin Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.

Has Galectin Therapeutics been receiving favorable news coverage?

News stories about GALT stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galectin Therapeutics earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Galectin Therapeutics.

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a decrease in short interest in the month of August. As of August 15th, there was short interest totalling 3,957,700 shares, a decrease of 11.6% from the July 15th total of 4,478,900 shares. Based on an average daily trading volume, of 339,700 shares, the short-interest ratio is currently 11.7 days. Currently, 11.5% of the company's stock are sold short. View Galectin Therapeutics' Current Options Chain.

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 69)
  • Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
  • Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.49%), Vanguard Group Inc. (3.80%), Advisor Group Inc. (1.77%), D.A. Davidson & CO. (1.73%), Cambridge Investment Research Advisors Inc. (0.41%) and Northern Trust Corp (0.29%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

Which institutional investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold Galectin Therapeutics company stock in the last year include Gilbert F Amelio and Marc Rubin. View Insider Buying and Selling for Galectin Therapeutics.

Which institutional investors are buying Galectin Therapeutics stock?

GALT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Advisor Group Inc., Cutter & CO Brokerage Inc., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Cambridge Investment Research Advisors Inc. and Northern Trust Corp. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin and Richard E Uihlein. View Insider Buying and Selling for Galectin Therapeutics.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $3.61.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $204.44 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is http://www.galectintherapeutics.com/.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  292 (Thanks for Voting!)
Underperform Votes:  247 (Thanks for Voting!)
Total Votes:  539
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel